In our study, one of the largest published phase II study testing bevacizumab as neoadjuvant treatment of BC, all included patients had HER2-negative disease and 43 (60 %) were HR+: moreover, the median tumor size (physical examination) was high (5 cm). Here, ERBB2 is linked to breast cancer.